Navigation Links
Labopharm Reports Results for Third Quarter Fiscal 2007
Date:11/9/2007

- Quarter Highlighted by Continued Momentum in Global Commercialization Program for Once-Daily Tramadol and Completion of Enrolment for Once-Daily

Trazodone Phase III Study -

LAVAL, QC, Nov. 9 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today reported its results for the third quarter of fiscal 2007, ended September 30, 2007. All figures are in Canadian dollars unless otherwise stated.

Recent Developments

Once-Daily Tramadol Global Commercialization Program

Sales of Labopharm's once-daily tramadol product for the third quarter of fiscal 2007 increased to $2.8 million from $1.1 million for the third quarter of fiscal 2006, the result of product shipments to a larger number of markets in the third quarter of fiscal 2007, as well as higher average selling prices in the third quarter of fiscal 2007, primarily due to the launch of the product in Canada, where selling prices are higher than in Europe. Once-daily tramadol sales for the first nine-months of fiscal 2007 increased to $10.4 million from $4.0 million for the same period of fiscal 2006. Adjusted gross margin for the third quarter and first nine months of fiscal 2007 increased to 56% and 50%, respectively, from 37% and 44% for the corresponding periods in 2006.

"While our quarterly product revenue will continue to fluctuate with the timing of orders typically associated with the early stages of product launches, our once-daily tramadol product is steadily achieving penetration of our target market(1) in Europe with our market share(2) reaching almost 4% in September," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "Our product has met with particular success in Spain, where it achieved a market share in September of almost 14%. We are confident that we can achieve similar results in other markets as we continue to address the initial challenges in some of those countries."

Labopharm and it------------------------------------------------------------------------

444 563 1,646 1,211

-------------------------------------------------------------------------

-------------------------------------------------------------------------

NET LOSS FOR THE PERIOD (9,031) (4,361) (26,539) (16,700)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

NET LOSS PER SHARE -

BASIC AND DILUTED (0.16) (0.08) (0.47) (0.33)

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Weighted average number

of common shares

outstanding 56,817,963 56,747,093 56,795,545 50,938,493

-------------------------------------------------------------------------

-------------------------------------------------------------------------

INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

For the: Three months ended Nine months ended

Sept 30, Sept 30, Sept 30, Sept 30,

2007 2006 2007 2006

(Thousands of Canadian

dollars) $ $ $ $

-------------------------------------------------------------------------

OPERATING ACTIVITIES

Net loss for the period (9,031) (4,361) (26,539) (16,700)

Items not affecting cash:

Depreciation of property,

plant and equipment 448 375 1,304 1,105

Amortization of intangible

assets 62 55 178 171

Amortization of deferred

financing costs - 51 - 162

Amortization of premium

or discounts on

marketable securities 57 - 207 -

Impairment loss on

long-term investment 874 - 874 -

Non-cash financial expenses 30 - 107 -

Unrealized foreign exchange

loss (gain) (106) (74) 282 (547)

Future income tax (64) (35) (64) (71)

Stock-based compensation 674 492 3,573 1,857

-------------------------------------------------------------------------

(7,056) (3,497) (20,078) (14,023)

Net change in non-cash

operating items 1,008 (6,274) 1,116 (15,941)

-------------------------------------------------------------------------

(6,048) (9,771) (18,962) (29,964)

-------------------------------------------------------------------------

INVESTING ACTIVITIES

Acquisition of marketable

securities (11,733) (73,741) (64,980) (99,138)

Proceeds from disposals of

marketable securities 3,498 2,500 3,498 2,500

Proceeds from maturities

of marketable securities 15,491 4,585 81,876 20,499

Acquisition of property,

plant and equipment (454) (437) (1,600) (1,018)

Acquisition of intangible

assets (334) (25) (457) (690)

-------------------------------------------------------------------------

6,468 (67,118) 18,337 (77,847)

-------------------------------------------------------------------------

FINANCING ACTIVITIES

Repayment of capital lease

obligations (24) (21) (71) (61)

Repayment of long-term debt (1,004) (903) (3,061) (2,307)

Proceeds from issuance of

capital stock - 120 225 114,664

Issuance costs of capital

stock - (1,456) - (9,240)

-------------------------------------------------------------------------

(1,028) (2,260) (2,907) 103,056

-------------------------------------------------------------------------

Foreign exchange loss on

cash held in foreign

currencies (207) (12) (1,121) (9)

Net decrease in cash and

cash equivalents during

the period (815) (79,161) (4,653) (4,764)

Cash and cash equivalents,

beginning of period 9,884 94,679 13,722 20,282

-------------------------------------------------------------------------

Cash and cash equivalents,

end of period 9,069 15,518 9,069 15,518

-------------------------------------------------------------------------

-------------------------------------------------------------------------

Cash flows include the

following items:

Interest paid 328 483 1,107 1,542

Income taxes paid (received) (430) 31 (902) 145

-------------------------------------------------------------------------

-------------------------------------------------------------------------

CONSOLIDATED BALANCE SHEETS

(Unaudited)

As at As at

September 30, December 31,

2007 2006

(Thousands of Canadian dollars) $ $

-------------------------------------------------------------------------

ASSETS

Current

Cash and cash equivalents 9,069 13,722

Available-for-sale marketable securities 59,370 85,747

Accounts receivable 5,005 4,002

Research and development tax credits receivable 1,264 1,869

Income taxes receivable - 939

Inventories 3,258 5,287

Prepaid expenses and other assets 1,705 1,384

-------------------------------------------------------------------------

Total current assets 79,671 112,950

-------------------------------------------------------------------------

Restricted long-term investments 1,273 1,280

Long-term investment 4,867 -

Property, plant and equipment, net 10,845 10,909

Intangible assets 3,484 3,205

Deferred financing costs - 156

Future income tax asset 198 134

-------------------------------------------------------------------------

100,338 128,634

-------------------------------------------------------------------------

-------------------------------------------------------------------------

LIABILITIES AND SHAREHOLDERS' EQUITY

Current

Accounts payable and accrued liabilities 9,460 8,908

Current portion of deferred revenue 4,326 7,916

Current portion of obligations under capital leases 163 94

Current portion of long-term debt 3,890 4,425

-------------------------------------------------------------------------

Total current liabilities 17,839 21,343

-------------------------------------------------------------------------

Deferred revenue 18,142 16,593

Obligations under capital leases 5,678 5,746

Long-term debt - 3,396

-------------------------------------------------------------------------

Total liabilities 41,659 47,078

-------------------------------------------------------------------------

Shareholders' equity

Common shares, no par value, unlimited shares

authorized, 56,817,963 and 56,747,963 issued

and outstanding as at September 30, 2007 and as

at December 31, 2006, respectively 241,955 241,588

Contributed surplus 11,848 8,417

Deficit (194,988) (168,449)

Accumulated other comprehensive loss (136) -

-------------------------------------------------------------------------

Total shareholders' equity 58,679 81,556

-------------------------------------------------------------------------

100,338 128,634

-------------------------------------------------------------------------

-------------------------------------------------------------------------

s marketing partner, Paladin Labs Inc., launched once-daily tramadol in Canada under the brand name Tridural(TM). The Company also completed licensing and distribution agreements for once-daily tramadol for South Korea with WhanIn Pharmaceutical Co., Ltd., for Greece with Lavipharm S.A. and for Israel with Dexcel Pharma Technologies Ltd. Labopharm expects its product to be launched in the South Korean and Greek markets in 2008. Labopharm's formulation is currently under regulatory review in Israel and the Company expects a response from the Israeli regulatory authority by mid-2008.

To date, Labopharm has secured marketing partners for its once-daily tramadol in more than 50 countries worldwide and regulatory approval in 25 countries. The Company's partners will continue to launch its product in additional markets, globally, throughout 2008.

In the U.S., Labopharm continues to vigorously pursue regulatory approval of its once-daily tramadol, appealing the U.S. Food and Drug Administration's (FDA) decision in its Approvable Letter through initiation of the Agency's Formal Dispute Resolution process. The Company believes that it has met the statutory standards for approval of its formulation and that appealing the FDA's decision through this process represents its best opportunity to expeditiously resolve this matter.

---------------------------------

(1) Labopharm's target market consists of the market for

immediate-release, twice-daily, once-daily and drop formulations of

tramadol.

(2) Includes France, Germany, the United Kingdom, Spain and Italy.

Once-Daily Trazodone Development Program

Labopharm has completed patient enrolment in its North American Phase III clinical trial for its once-daily formulation of the antidepressant trazodone, ahead of schedule. More than 400 patients are enrolled in the study.

"Our once-daily formulation represents the opportunity to address significant unmet needs in the treatment of depression," said Mr. Howard-Tripp. "Trazodone has a proven history of efficacy and we believe that by controlling the blood concentration levels through our Contramid(R) controlled-release technology, we can offer a once-daily formulation with a potentially improved side effect profile that takes advantage of trazodone's unique sedative effects, eliminating the need for adjunctive therapy often associated with other anti-depressants to address related conditions such as poor sleep quality. We look forward to reporting data from our Phase III study in the second quarter of next year."

Other Development Programs

Labopharm continues to advance the development programs for other product candidates in its pipeline, including its programs to develop a twice-daily tramadol-acetaminophen combination formulation and a twice-daily acetaminophen formulation, both of which are based on the Company's proprietary Contramid(R) technology. The Company is currently in the process of preparing for pivotal studies for the tramadol-acetaminophen formulation, which it expects to begin imminently.

Financial Results

Revenue for the third quarter of fiscal 2007 increased to $5.1 million from $3.3 million for the third quarter of fiscal 2006. Product sales increased to $2.8 million from $1.1 million with the increase being the result of higher volumes due to shipments of once-daily tramadol to a larger number of markets in the third quarter of fiscal 2007 compared to the third quarter of fiscal 2006, as well as higher average selling prices in the third quarter of fiscal 2007, primarily as a result of launch of the product in Canada, where selling prices are higher than in Europe. Product sales for the third quarter of fiscal 2007 consisted of follow-on shipments of once-daily tramadol to our marketing partners in Europe for distribution in various markets, as well as initial shipments to Paladin Labs Inc. for distribution in Canada.

Gross margin (as a percentage of product sales revenue), excluding a non-recurring favourable adjustment of $236,000, for the third quarter of fiscal 2007 increased to 56% from 37% for the third quarter of fiscal 2006. The increase in adjusted gross margin compared to the third quarter of last year was due to lower manufacturing costs and higher average selling prices per tablet resulting primarily from the launch in Canada, which were partially offset by a royalty expense payable to an affiliate of Purdue Pharma to avoid any potential conflict with respect to patents.

Licensing revenue for the third quarter of fiscal 2007 was $1.1 million and represented a portion of licensing payments received from the Company's licensing and distribution partners for once-daily tramadol. Licensing revenue for the third quarter of fiscal 2006 was $2.2 million. The decrease in licensing revenues was primarily the result of the extensions of the estimated term over which the Company is recognizing the US$20 million up-front payment previously received from Purdue Pharma.

Revenue from research and development collaborations for the third quarter of fiscal 2007 was $1.2 million and was related to the ongoing development of an additional strength of Labopharm's once-daily tramadol product. The Company did not generate revenue from research and development collaborations in the corresponding quarter of last year.

Research and development expenses before research and development tax credits for the third quarter of fiscal 2007 increased to $7.9 million from $3.4 million for the third quarter of fiscal 2006. The increase was primarily due to the Phase III clinical trial for once-daily trazodone that was initiated in the second quarter of fiscal 2007, several pharmacokinetic studies for additional development programs and the general increase in the Company's research and development activities. Research and development tax credits for the third quarter of fiscal 2007 were unchanged from the corresponding quarter of fiscal 2006 at $0.8 million.

Selling, general and administrative expenses for the third quarter of fiscal 2007 increased to $4.6 million from $4.1 million for the third quarter of fiscal 2006. The increase is due primarily to increased headcount and related compensation expense and increased sales and marketing and other operational costs as the Company transitions from a research and development company to a commercial operation.

At September 30, 2007, the Company held investments in Canadian third party asset-backed commercial paper (ABCP) with an original cost of $5.6 million. When acquired, these investments were rated R1 (High) by Dominion Bond Rating service (DBRS), the highest credit rating issued for commercial paper. These investments matured in October 2007 but, as a result of liquidity issues in the ABCP market, did not settle on maturity. As a result, the Company has adjusted the estimated fair value of the investment and taken a charge in the third quarter of $0.9 million and classified its ABCP as a long-term investment.

Net loss for the third quarter of fiscal 2007 was $9.0 million, or $0.16 per share, compared with $4.4 million, or $0.08 per share, for the third quarter of fiscal 2006.

Cash, cash equivalents and marketable securities at September 30, 2007 were $68.4 million ($73.3 million including the ABCP that was classified as a long-term investment) compared with $99.5 million at December 31, 2007. Excluding the reclassification and write down of the ABCP discussed above, Labopharm's cash, cash equivalents and marketable securities decreased $25.3 million compared to December 31, 2007. This decrease was primarily the result of the use of funds for operating activities.

For the nine-month period ended September 30, 2007, revenue increased to $16.3 million from $10.7 million for the first nine months of 2006. Product sales increased to $10.4 million from $4.0 million, primarily the result of higher volumes due to shipments of once-daily tramadol to a larger number of markets in the first nine months of fiscal 2007 compared to the first nine months of fiscal 2006.

Gross margin for the first nine months of fiscal 2007, excluding the provision for once-daily tramadol pre-launch inventory and related deposits to manufacturers taken in the second quarter following the delay in the anticipated U.S. launch of once-daily tramadol, net of the non-recurring favourable adjustment discussed for the quarter, increased to 50% from 44% for the first nine months of fiscal 2006. The increase in adjusted gross margin for the first nine months of 2007 was due to higher average selling prices, primarily attributable to the Canadian launch of once-daily tramadol and lower manufacturing costs, which were partially offset by a royalty expense payable to an affiliate of Purdue Pharma to avoid any potential conflict with respect to patents.

Licensing revenue for the first nine months of fiscal 2007 was $4.8 million, and represented a portion of licensing payments received from the Company's licensing and distribution partners for once-daily tramadol. Licensing revenue for the first nine months of fiscal 2006 was $6.8 million. The decrease in licensing revenues was the result of the extensions of the estimated term over which the Company is recognizing the US$20 million up- front payment previously received from Purdue Pharma.

Research and development expenses before research and development tax credits for the first nine months of fiscal 2007 increased to $19.5 million from $14.3 million for the first nine months of fiscal 2006. The increase was primarily due to the Phase III clinical trial for once-daily trazodone that was initiated in the second quarter of fiscal 2007, several pharmacokinetic studies for additional development programs and the general increase in the Company's research and development activities. Research and development tax credits for the first nine months of fiscal 2007 were $2.4 million compared to $1.8 million for the first nine months of fiscal 2006.

Selling, general and administrative costs for the first nine months of fiscal 2007 increased to $16.0 million from $11.1 million for the first nine months of fiscal 2006. The rationale for the increase is consistent with that for the third quarter and also includes an increase in non-cash stock-based compensation expense of $1.3 million.

Net loss for the first nine months of fiscal 2007 was $26.5 million, or $0.47 per share, compared to $16.7 million, or $0.33 per share for the first nine months of fiscal 2006.

Labopharm continues to expect global sales of its once-daily tramadol product to be variable from quarter to quarter as a result of pipeline fill and other supply chain and market dynamics associated with the early stages of product launches. Labopharm believes that the continued penetration of markets in which its product has already been launched, as well as additional product launches globally, will result in quarter over quarter growth in product sales.

Conference Call

Labopharm will host a conference call today (Friday, November 9, 2007 at 8:30 a.m. ET) to discuss its third quarter fiscal 2007 results. To access the conference call by telephone, dial (416) 644-3427 or 1-800-589-8577. Please connect approximately five minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Friday, November 16, 2007 at midnight. To access the archived conference call, dial (416) 640-1917 or 1-877-289-8525 and enter the reservation number 21251082 followed by the number sign. A live audio webcast of the conference call will be available at http://www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become a fully integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.

INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

For the: Three months ended Nine months ended

Sept 30, Sept 30, Sept 30, Sept 30,

2007 2006 2007 2006

(Thousands of Canadian

dollars, except share

and per share amounts) $ $ $ $

-------------------------------------------------------------------------

REVENUE

Product sales 2,818 1,097 10,359 4,044

Licensing 1,058 2,229 4,786 6,672

Research and development

collaborations 1,217 - 1,217 -

-------------------------------------------------------------------------

5,093 3,326 16,362 10,716

-------------------------------------------------------------------------

EXPENSES

Cost of goods sold

(excluding amortization) 1,012 691 6,716 2,267

Research and development

expenses, net 7,171 2,611 17,088 12,466

Selling, general and

administrative expenses 4,596 4,069 16,048 11,060

Financial expenses 434 644 1,474 2,056

Impairment loss on

long-term investment 874 - 874 -

Depreciation and

amortization 510 430 1,482 1,276

Interest income (810) (1,271) (2,707) (2,277)

Foreign exchange loss (gain) (107) (50) 280 (643)

-------------------------------------------------------------------------

13,680 7,124 41,255 26,205

-------------------------------------------------------------------------

LOSS BEFORE INCOME TAXES (8,587) (3,798) (24,893) (15,489)

Provision for income taxes

Current 508 598 1,710 1,282

Future (64) (35) (64) (71)

-
'/>"/>

SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. Haemacure Reports Third Quarter 2007 Results
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... ... EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference ... estimated 5000 perioperative nurses in attendance to study the latest evidence-based recommendations ...
(Date:2/6/2016)... ... ... Shark Finds and Kevin Harrington, along with the Product Managers ... Belly Bands. , Having a dog is great—except when it wets every couch, bed, ... works, get Belly Bands, the easiest way to stop dogs from wetting on ...
(Date:2/5/2016)... NY (PRWEB) , ... February 05, 2016 , ... Love ... long-stem roses in a variety of colors, assortments and packaging. This staple for Valentine’s ... any King Kullen location. , For Valentine’s Day, not only are long-stem roses ...
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, MD and ... their Napa Valley office. The technique utilizes the body’s own healing abilities to ... Dr. Furnas, are part of only a select few cosmetic surgeons bringing this ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016   Bernstein Liebhard LLP ... filed in the United States District Court for the District ... class (the "Class") consisting of all persons or entities who ... "Company") (NASDAQ: INSY ) from March 3, 2015 through ... and certain of its officers with violations of the Securities ...
(Date:2/4/2016)... Feb. 4, 2016 Summary Breast cancer, ... and the most common cancer in women worldwide, accounting ... exceedingly prevalent. The number of women diagnosed with breast ... the number of deaths has declined due to earlier ... has been revolutionized in the past four decades, especially ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
Breaking Medicine Technology: